Comparison of two regimens of vitamin D supplementation for vitamin D-deficient neonates

Share this Article

Singapore Med J 2014; 55(5): 266-270; http://dx.doi.org/10.11622/smedj.2014070
Comparison of two regimens of vitamin D supplementation for vitamin D-deficient neonates

Shakiba M, Pahloosye A, Mirouliaei M, Islami Z
Correspondence: Dr Mehrdad Shakiba, shakiba@ssu.ac.ir

ABSTRACT
INTRODUCTION Vitamin D deficiency is common in pregnant women, and supplementation of vitamin D is necessary for the infants of these women. This study explored the efficacy of an alternative way of vitamin D supplementation in an area with a high prevalence of vitamin D deficiency in mothers.
METHODS This was a non-randomised clinical trial conducted in 2010 in Yazd, Iran. Full-term healthy infants born to vitamin D-deficient mothers (n = 82) were divided into the high-dose regimen (HDR; single oral bolus 30,000 IU vitamin D3, n = 34) and the standard-dose regimen (SDR; 400 IU/day vitamin D3 within two weeks of life, n = 48) groups. 25-hydroxyvitamin D (25OHD) was measured using chemiluminescent immunoassays, and 25OHD level > 20 ng/mL was deemed sufficient.
RESULTS Over 90% of infants in the HDR group attained vitamin D sufficiency within one month, while comparable sufficiency was reached in the SDR group only after four months. At two months, the proportion of infants attaining 25OHD > 30 ng/mL was 93.3% and 27.9% in the HDR and SDR groups, respectively (p = 0.003). None of our infants achieved 25OHD levels > 100 ng/mL.
CONCLUSION For infants born to vitamin D-deficient mothers, oral supplementation of 30,000 IU vitamin D3 during the first month of life, followed by a routine recommended dose of 400 IU/day, should be considered. The four-month lag for attaining vitamin D sufficiency in 90% of infants in the SDR group may have clinical implications and should be further investigated.

Keywords: infant, supplement, vitamin D
Singapore Med J 2014; 55(5): 266-270; http://dx.doi.org/10.11622/smedj.2014070

REFERENCES

1. Wagner CL, Greer FR. American Academy of Pediatrics Section on Breastfeeding; American Academy of Pediatrics Committee on Nutrition. Prevention of rickets and vitamin D deficiency in infants, children, and adolescents. Pediatrics 2008; 122:1142-52.
http://dx.doi.org/10.1542/peds.2008-1862
 
2. No authors listed. Vitamin D supplementation: Recommendations for Canadian mothers and infants. Paediatr Child Health 2007; 12:583-98.
 
3. Holick MF, Binkley NC, Bischoff-Ferrari HA, et al. Evaluation, treatment, and prevention of vitamin D deficiency: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 2011; 96:1911-30.
http://dx.doi.org/10.1210/jc.2011-0385
 
4. Bowyer L, Catling-Paull C, Diamond T, et al. VitaminD, PTH and calcium levels in pregnant women and their neonates. Clin Endocrinol (Oxf) 2009; 70:372-7.
http://dx.doi.org/10.1111/j.1365-2265.2008.03316.x
 
5. Palacios C, Gonzalez L. Is vitamin D deficiency a major global public health problem? J Steroid Biochem Mol Biol 2013 Nov 12.
http://dx.doi.org/10.1016/j.jsbmb.2013.11.003
 
6. Novakovic B, Galati JC, Chen A, et al. Maternal vitamin D predominates over genetic factors in determining neonatal circulating vitamin D concentrations. Am J Clin Nutr 2012; 96:188-95.
http://dx.doi.org/10.3945/ajcn.112.035683
 
7. Searing DA, Leung DY. Vitamin D in atopic dermatitis, asthma and allergic diseases. Immunol Allergy Clin North Am 2010; 30:397-409.
http://dx.doi.org/10.1016/j.iac.2010.05.005
 
8. Kamen DL, Tangpricha V. Vitamin D and molecular actions on the immune system modulation of innate and autoimmunity. J Mol Med (Berl) 2010; 88:441-50.
http://dx.doi.org/10.1007/s00109-010-0590-9
 
9. Bikle DD. Vitamin D regulation of immune function. Vitam Horm 2011; 86:1-21.
http://dx.doi.org/10.1016/B978-0-12-386960-9.00001-0
 
10. Hyppönen E, Läärä E, Reunanen A, et al. Intake of vitamin D and risk of type 1 diabetes: a birth-cohort study. Lancet 2001; 358:1500-3.
http://dx.doi.org/10.1016/S0140-6736(01)06580-1
 
11. Dijkstra SH, van Beek A, Janssen JW, et al. Prevalence of vitamin D deficiency in newborn infants of high-risk mothers. Arch Dis Child 2007; 92:750-3.
PMid:17715438 PMCid:PMC2084031
 
12. Zeghoud F, Vervel C, Guillozo H, et al. Subclinical vitamin D deficiency in neonates: definition and response to vitamin D supplements. Am J Clin Nutr 1997; 65:771-8
PMid:9062528
 
13. Vervel C, Zeghoud F, Boutignon H, et al. [Fortified milk and supplements of oral vitamin D. Comparison of the effect of two doses of vitamin D (500 and 1,000 UI/d) during the first trimester of life]. Arch Pediatr 1997; 4:126-32. French.
http://dx.doi.org/10.1016/S0929-693X(97)86154-4
 
14. Wagner CL, Howard C, Hulsey TC, et al. Circulating 25-hydroxyvitamin d levels in fully breastfed infants on oral vitamin D supplementation. Int J Endocrinol 2010; 2010:235035.
 
15. Abrams SA, Hawthorne KM, Rogers SP, Hicks PD, Carpenter TO. Effects of ethnicity and vitamin D supplementation on vitamin D status and changes in bone mineral content in infants. BMC Pediatr 2012; 12:6.
http://dx.doi.org/10.1186/1471-2431-12-6
 
16. Onal H, Adal E, Alpaslan S, Ersen A, Aydin A: Is daily 400 IU of vitamin D supplementation appropriate for every country: a cross-sectional study. Eur J Nutr 2010; 49:395-400.
http://dx.doi.org/10.1007/s00394-010-0097-8
 
17. Merewood A, Mehta SD, Grossman X, et al. Vitamin D status among 4-month-old infants in New England: a prospective cohort study. J Hum Lact 2012; 28:159-66.
http://dx.doi.org/10.1177/0890334411434802
 
18. Kim MJ, Na B, No SJ, et al. Nutritional status of vitamin D and the effect of vitamin D supplementation in Korean breast-fed infants. J Korean Med Sci 2010; 25:83-9.
http://dx.doi.org/10.3346/jkms.2010.25.1.83
 
19. Greer FR. 25-Hydroxyvitamin D: functional outcomes in infants and young children. Am J Clin Nutr 2008; 88:529S-533S.
PMid:18689395
 
20. Hollis BW, Wagner CL. Vitamin D requirements during lactation: high-dose maternal supplementation as therapy to prevent hypovitaminosis D for both the mother and the nursing infant. Am J Clin Nutr 2004; 80:1752S-8S.
PMid:15585800
 
21. Haggerty LL. Maternal supplementation for prevention and treatment of vitamin D deficiency in exclusively breastfed infants. Breastfeed Med 2011; 6:137-44.
http://dx.doi.org/10.1089/bfm.2010.0025
 
22. Shakiba M, Sadr S, Nefei Z, et al. Combination of bolus dose vitamin D with routine vaccination in infants: a randomised trial. Singapore Med J 2010; 51:440-5.
PMid:20593151

Clinical characteristics and mortality risk prediction in critically ill children in Malaysian Borneo

Share this Article

Singapore Med J 2014; 55(5): 261-265; http://dx.doi.org/10.11622/smedj.2014069
Clinical characteristics and mortality risk prediction in critically ill children in Malaysian Borneo

Ganesan I, Thomas T, Ng FE, Soo TL
Correspondence: Dr Indra Ganesan, Indra.Ganesan@kkh.com.sg

ABSTRACT
INTRODUCTION Mortality risk prediction scores are important for benchmarking quality of care in paediatric intensive care units (PICUs). We aimed to benchmark PICU outcomes at our hospital against the Pediatric Index of Mortality 2 (PIM2) mortality risk prediction score, and evaluate differences in diagnosis on admission and outcomes between Malaysian and immigrant children.
METHODS We prospectively collected demographic and clinical data on paediatric medical patients admitted to the PICU of Sabah Women’s and Children’s Hospital in Kota Kinabalu, Sabah, Malaysia. The PIM2 risk score for mortality was tabulated.
RESULTS Of the 131 patients who met the inclusion criteria, data was available for 115 patients. The mean age of the patients was 2.6 ± 3.8 years, with 79% of the cohort aged less than five years. Patients were mainly of Kadazan (38%) and Bajau (30%) descent, and 26% of patients were non-citizens. Leading diagnoses on admission were respiratory (37%), neurological (18%) and infectious (17%) disorders. Out of the 29 patients who died, 23 (79%) were Malaysians and the main mortality diagnostic categories were respiratory disorder (22%), septicaemia (22%), haemato-oncological disease (17%) and neurological disorder (13%). Calculated standardised mortality ratios (SMRs) were not significantly > 1 for any patient category for variables such as age and admission diagnosis. However, infants less than two years old with comorbidities were significantly worse (SMR 2.61, 95% confidence interval 1.02–6.66).
CONCLUSION The patient profile at our centre was similar to that reported from other PICUs in Asia. The PIM2 score is a useful mortality risk prediction model for our population.

Keywords: mortality risk prediction scores, paediatric intensive care
Singapore Med J 2014; 55(5): 261-265; http://dx.doi.org/10.11622/smedj.2014069

REFERENCES

1. Department of Statistics Malaysia. Population Distribution and Basic Demographic Characteristic Report 2010. Kuala Lumpur: Department of Statistics Malaysia; 2011.
 
2. Slater A, Shann F, Pearson G; Paediatric Index of Mortality (PIM) Study Group. PIM2: a revised version of the Paediatric Index of Mortality. Intensive Care Med 2003; 29:278-85.
PMid:12541154
 
3. Pollack MM, Patel KM, Ruttimann UE. PRISM III: an updated Pediatric Risk of Mortality score. Crit Care Med 1996; 24:743-52.
http://dx.doi.org/10.1097/00003246-199605000-00004
 
4. Choi KM, Ng DK, Wong SF, et al. Assessment of the Pediatric Index of Mortality (PIM) and the Pediatric Risk of Mortality (PRISM) III score for prediction of mortality in a paediatric intensive care unit in Hong Kong. Hong Kong Med J 2005; 11:97-103.
 
5. Pearson GA, Stickley J, Shann F. Calibration of the paediatric index of mortality in UK paediatric intensive care units. Arch Dis Child 2001; 84:125-8.
http://dx.doi.org/10.1136/adc.84.2.125
 
6. Singhal D, Kumar N, Puliyel JM, Singh SK, Srinivas V. Prediction of mortality by application of PRISM score in intensive care unit. Indian Pediatr 2001; 38:714-9.
PMid:11463958
 
7. Canonero I, Figueroa A, Cacciamano A, Olivier E, Cuestas E. [Validation of PRISM and PIM2 scores of mortality in a pediatric intensive care unit in Cordoba]. Arch Argent Pediatr 2010; 108:427-33. Spanish.
PMid:21132231
 
8. Gemke RJ, van Vught J. Scoring systems in pediatric intensive care: PRISM III versus PIM. Intensive Care Med 2002; 28:204-7.
http://dx.doi.org/10.1007/s00134-001-1185-2
 
9. Goh AY, Abdel-Latif Mel-A, Lum LC, Abu-Bakar MN. Outcome of children with different accessibility to tertiary pediatric intensive care in a developing country: a prospective cohort study. Intensive Care Med 2003; 29:97-102.
PMid:12528029
 
10. Wells M, Riera-Fanego JF, Luyt DK, Dance M, Lipman J. Poor discriminatory performance of the Pediatric Risk of Mortality (PRISM) score in a South African intensive care unit. Crit Care Med 1996; 24:1507-13.
http://dx.doi.org/10.1097/00003246-199609000-00013
 
11. Tan GH, Tan TH, Goh DY, Yap HK. Risk factors for predicting mortality in a paediatric intensive care unit. Ann Acad Med Singapore 1998; 27:813-8.
PMid:10101556
 
12. Prieto Espu-es S, López-Herce Cid J, Rey Galán C, et al. [Prognostic indexes of mortality in pediatric intensive care units]. An Pediatr 2007; 66:345-50. Spanish.
http://dx.doi.org/10.1157/13101237
 
13. The World Bank. World Bank Atlas Method. Washington: The World Bank; 2011 [online]. Available at: http://data.worldbank.org/about/country-classifications/world-bank-atlas.... Accessed 1 September 2011.
 
14. Department of Statistics Malaysia. Report on Household Income Expenditure Survey, Malaysia 2009/10. Kuala Lumpur: Department of Statistics Malaysia; 2011.
 
15. Hussain IH, Sofiah A, Ong LC, et al. Haemophilus influenzae meningitis in Malaysia. Pediatr Infect Dis J 1998; 17(9 Suppl):S189-90.
http://dx.doi.org/10.1097/00006454-199809001-00021
 
16. Malaysia: WHO and UNICEF estimates of national immunization coverage: 2010 revision. Available at: http://www.childinfo.org/filesMalaysia_1997_2010.pdf. Accessed 1 September 2011.
 
17. Thigpen MC, Whitney CG, Messonnier NE, et al. Bacterial meningitis in the United States, 1998-2007. N Engl J Med 2011; 364:2016-25.
http://dx.doi.org/10.1056/NEJMoa1005384
 
18. Wong SL, Muhammad Ismail HI, eds. Study On Under Five Deaths in Malaysia 1993-2003: Where and Why 5000 Children in Malaysia are dying every year? Kuala Lumpur: Ministry of Health Malaysia; 2008.
 
19. Marcin JP, Pollack MM. Review of the acuity scoring systems for the pediatric intensive care unit and their use in quality improvement. J Intensive Care Med 2007; 22:131-40.
http://dx.doi.org/10.1177/0885066607299492

Sleep-related breathing disorder is associated with hyperactivity in preschoolers

Share this Article

Singapore Med J 2014; 55(5): 257-260; http://dx.doi.org/10.11622/smedj.2014068
Sleep-related breathing disorder is associated with hyperactivity in preschoolers

Ren ZM, Qiu AL
Correspondence: Dr Zhimin Ren, rrzzmm1966@sina.com

ABSTRACT
INTRODUCTION Sleep problems are a prominent feature in children with attention deficit hyperactivity disorder (ADHD). Unlike existing studies that focused on extreme samples (i.e. normal vs. ADHD), our study investigated the associations of sleep-related behaviours and ADHD features in nonclinical Chinese preschoolers.
METHODS All participants were recruited via advertisements and screened for eligibility through a telephone interview prior to an onsite visit. The maternal reports of the Conners’ Parent Rating Scale (CPRS) and Pediatric Sleep Questionnaire (PSQ) were acquired from 110 Chinese preschoolers aged six years. Regression models were used to examine the association between CPRS and PSQ scores.
RESULTS The results obtained from regression models on the CPRS and PSQ scores of the 110 participants showed that none of the sleep-related behavioural measures (i.e. sleep-related breathing disorder [SRBD], snoring, daytime sleepiness, restless legs syndrome) was associated with inattention in our sample. However, worse SRBD was associated with higher hyperactivity.
CONCLUSION Our study underpins the importance of understanding the relationship between sleep-related behaviours and ADHD characteristics before the usual age of clinical diagnosis in children with ADHD.

Keywords: ADHD, Conners’ Parent Rating Scale, hyperactivity, inattention, sleep-related breathing disorder
Singapore Med J 2014; 55(5): 257-260; http://dx.doi.org/10.11622/smedj.2014068

REFERENCES

1. Polanczyk G, de Lima MS, Horta BL, Biederman J, Rohde LA. The worldwide prevalence of ADHD: a systematic review and metaregression analysis. Am J Psychiatry 2007; 164:942-8.
http://dx.doi.org/10.1176/appi.ajp.164.6.942
 
2. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders: DSM-IV. 4th ed. Washington (DC): American Psychiatric Association, 1994.
 
3. Oguzturk O, Ekici M, Cimen D, Ekici A, Senturk E. Attention deficit/hyperactivity disorder in adults with sleep apnea. J Clin Psychol Med Settings 2013; 20:234-9.
http://dx.doi.org/10.1007/s10880-012-9331-2
 
4. Kirov R, Uebel H, Albrecht B, et al. Attention-deficit/hyperactivity disorder (ADHD) and adaptation night as determinants of sleep patterns in children. Eur Child Adolesc Psychiatry 2012; 21:681-90.
http://dx.doi.org/10.1007/s00787-012-0308-3
 
5. Sadeh A, Pergamin L, Bar-Haim Y. Sleep in children with attention-deficit hyperactivity disorder: a meta-analysis of polysomnographic studies. Sleep Med Rev 2006; 10:381-98.
http://dx.doi.org/10.1016/j.smrv.2006.03.004
 
6. Gaultney JF, Terrell DF, Gingras JL. Parent-reported periodic limb movement, sleep disordered breathing, bedtime resistance behaviors, and ADHD. Behav Sleep Med 2005; 3:32-43.
http://dx.doi.org/10.1207/s15402010bsm0301_5
 
7. Marcotte AC, Thacher PV, Butters M, et al. Parental report of sleep problems in children with attentional and learning disorders. J Dev Behav Pediatr 1998; 19:178-86.
http://dx.doi.org/10.1097/00004703-199806000-00005
 
8. van der Heijden KB, Smits MG, Gunning WB. Sleep-related disorders in ADHD: a review. Clin Pediatr (Phila) 2005; 44:201-10.
http://dx.doi.org/10.1177/000992280504400303
 
9. Scott N, Blair PS, Emond AM, et al. Sleep patterns in children with ADHD: a population-based cohort study from birth to 11 years. J Sleep Res 2013; 22:121-8.
http://dx.doi.org/10.1111/j.1365-2869.2012.01054.x
 
10. Shur-Fen Gau S. Prevalence of sleep problems and their association with inattention/hyperactivity among children aged 6-15 in Taiwan. J Sleep Res 2006; 15:403-14.
http://dx.doi.org/10.1111/j.1365-2869.2006.00552.x
 
11. Wu YW, Xing G, Fuentes-Afflick E, et al. Racial, ethnic, and socioeconomic disparities in the prevalence of cerebral palsy. Pediatrics 2011; 127:e674-81.
http://dx.doi.org/10.1542/peds.2010-1656
 
12. Biederman J, Faraone SV. Attention-deficit hyperactivity disorder. Lancet 2005; 366:237-48.
http://dx.doi.org/10.1016/S0140-6736(05)66915-2
 
13. Biederman J, Mick E, Faraone SV, et al. Influence of gender on attention deficit hyperactivity disorder in children referred to a psychiatric clinic. Am J Psychiatry 2002; 159:36-42.
http://dx.doi.org/10.1176/appi.ajp.159.1.36
 
14. Arnold LE, Elliot M, Sachs L, et al. Effects of ethnicity on treatment attendance, stimulant response/dose, and 14-month outcome in ADHD. J Consult Clin Psychol 2003; 71:713-27.
http://dx.doi.org/10.1037/0022-006X.71.4.713
 
15. Gau SS, Soong WT, Chiu YN, Tsai WC. Psychometric properties of the Chinese version of the Conners' Parent and Teacher Rating Scales-Revised: Short Form. J Atten Disord 2006; 9:648-59.
http://dx.doi.org/10.1177/1087054705284241
 
16. Wang CH, Yang CM, Huang YS. The Validation and Reliability of Chinese Version of the Pediatric Sleep Questionnaire for Patients with Sleep Breathing Problem. Taiwan J Psychiatry 2012; 26:177-86.
 
17. Owens JA. The ADHD and sleep conundrum: a review. J Dev Behav Pediatr 2005; 26:312-22.
http://dx.doi.org/10.1097/00004703-200508000-00011
 
18. Cohen-Zion M, Ancoli-Israel S. Sleep in children with attention-deficit hyperactivity disorder (ADHD): a review of naturalistic and stimulant intervention studies. Sleep Med Rev 2004; 8:379-402.
http://dx.doi.org/10.1016/j.smrv.2004.06.002
 
19. Corkum P, Tannock R, Moldofsky H. Sleep disturbances in children with attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 1998; 37:637-46.
http://dx.doi.org/10.1097/00004583-199806000-00014
 
20. Silvestri R, Gagliano A, Arico I, et al. Sleep disorders in children with attention-deficit/hyperactivity disorder (ADHD) recorded overnight by video-polysomnography. Sleep Med 2009; 10:1132-8.
http://dx.doi.org/10.1016/j.sleep.2009.04.003
 
21. O'Brien LM, Holbrook CR, Mervis CB, et al. Sleep and neurobehavioral characteristics of 5- to 7-year-old children with parentally reported symptoms of attention-deficit/hyperactivity disorder. Pediatrics 2003; 111:554-63.
http://dx.doi.org/10.1542/peds.111.3.554
 
22. Konofal E, Lecendreux M, Cortese S. Sleep and ADHD. Sleep Med 2010; 11:652-8.
http://dx.doi.org/10.1016/j.sleep.2010.02.012
 
23. Owens JA, Maxim R, Nobile C, McGuinn M, Msall M. Parental and self-report of sleep in children with attention-deficit/hyperactivity disorder. Arch Pediatr Adolesc Med 2000; 154:549-55.
http://dx.doi.org/10.1001/archpedi.154.6.549
 
24. Ali NJ, Pitson DJ, Stradling JR. Snoring, sleep disturbance, and behaviour in 4-5 year olds. Arch Dis Child 1993; 68:360-6.
http://dx.doi.org/10.1136/adc.68.3.360
 
25. Ali NJ, Pitson D, Stradling JR. Sleep disordered breathing: effects of adenotonsillectomy on behaviour and psychological functioning. Eur J Pediatr 1996; 155:56-62.
http://dx.doi.org/10.1007/BF02115629
 
26. Beebe DW, Gozal D. Obstructive sleep apnea and the prefrontal cortex: towards a comprehensive model linking nocturnal upper airway obstruction to daytime cognitive and behavioral deficits. J Sleep Res 2002; 11:1-16.
http://dx.doi.org/10.1046/j.1365-2869.2002.00289.x
 
27. O'Brien LM, Ivanenko A, Crabtree VM, et al. Sleep disturbances in children with attention deficit hyperactivity disorder. Pediatr Res 2003; 54:237-43.
http://dx.doi.org/10.1203/01.PDR.0000072333.11711.9A
 
28. Chervin RD, Archbold KH. Hyperactivity and polysomnographic findings in children evaluated for sleep-disordered breathing. Sleep 2001; 24:313-20.
PMid:11322714
 
29. Picchietti DL, Underwood DJ, Farris WA, et al. Further studies on periodic limb movement disorder and restless legs syndrome in children with attention-deficit hyperactivity disorder. Mov Disord 1999; 14:1000-7.
http://dx.doi.org/10.1002/1531-8257(199911)14:6<1000::AID-MDS1014>3.0.CO;2-P
 
30. Konofal E, Cortese S. Restless legs syndrome and attention-deficit/hyperactivity disorder. Ann Neurol 2005; 58:341-2.
http://dx.doi.org/10.1002/ana.20562
 
31. Cortese S, Konofal E, Lecendreux M, et al. Restless legs syndrome and attention-deficit/hyperactivity disorder: a review of the literature. Sleep 2005; 28:1007-13.
PMid:16218085
 
32. Qiu A, Crocetti D, Adler M, et al. Basal ganglia volume and shape in children with attention deficit hyperactivity disorder. Am J Psychiatry 2009; 166:74-82.
http://dx.doi.org/10.1176/appi.ajp.2008.08030426

Clinical profile and visual outcome of traumatic paediatric cataract in suburban Malaysia: a ten-year experience

Share this Article

Singapore Med J 2014; 55(5): 253-256; http://dx.doi.org/10.11622/smedj.2014067
Clinical profile and visual outcome of traumatic paediatric cataract in suburban Malaysia: a ten-year experience

Adlina AR, Chong YJ, Shatriah I
Correspondence: A/Prof Shatriah Ismail, shatriah@kck.usm.my

ABSTRACT
INTRODUCTION Available data on traumatic cataract in Asian children is primarily confined to South Asian countries. We aimed to describe the demographics, nature of injury and visual outcomes of Malaysian children with traumatic cataract from a suburban area, and discuss the literature on Asian children with this condition.
METHODS We conducted a retrospective study of 29 children below 17 years of age who were diagnosed with traumatic paediatric cataract and who attended Hospital Universiti Sains Malaysia, Kelantan, Malaysia, between January 2000 and December 2010. Follow-up periods ranged from 12 to 120 months. Demographic data, clinical features, mechanism and extent of injury, and final visual outcome were recorded.
RESULTS The study population was predominantly male. The right eye was injured in 62.07% of patients. A majority of patients had penetrating injuries, with the most common cause being injury by an organic foreign body (24.14%). Presenting visual acuity worse than 6/60 was observed in 68.97% of patients. Only 34.48% of patients had a final corrected visual acuity of 6/12 and better. 55.18% of patients were operated on within less than one month of their injuries. A majority of children sustained concurrent injuries to the anterior segment structures. Corneal opacity and amblyopia were the most common causes of poor final visual acuity.
CONCLUSION Health education and awareness are essential tools that can prevent avoidable blindness due to traumatic cataract in the paediatric population. The importance of rehabilitation programmes for these patients should be emphasised.

Keywords: Malaysian children, suburban area, traumatic paediatric cataract
Singapore Med J 2014; 55(5): 253-256; http://dx.doi.org/10.11622/smedj.2014067

REFERENCES

1. Maida JM, Mathers K, Alley CL. Pediatric ophthalmology in the developing world. Curr Opin Ophthalmol 2008; 19:403-8.
http://dx.doi.org/10.1097/ICU.0b013e328309f180
 
2. Gilbert C, Foster A. Childhood blindness in the context of VISION 2020--the right to sight. Bull World Health Organ 2001; 79:227-32.
PMid:11285667 PMCid:PMC2566382
 
3. Gilbert C, Muhit M. Eye conditions and blindness in children: priorities for research, programs, and policy with a focus on childhood cataract. Indian J Ophthalmol 2012; 60:451-5.
http://dx.doi.org/10.4103/0301-4738.100548
 
4. Gogate P, Sahasrabudhe M, Shah M, Patil S, Kulkarni A. Causes, epidemiology, and long-term outcome of traumatic cataracts in children in rural India. Indian J Ophthalmol 2012; 60:481-6.
http://dx.doi.org/10.4103/0301-4738.100557
 
5. Shah MA, Shah SM, Appleware AH, et al. Visual outcome of traumatic cataract in pediatric age group. Eur J Ophthalmol 2012; 22:956-63.
http://dx.doi.org/10.5301/ejo.5000111
 
6. Ram J, Verma N, Gupta N, Chaudhary M. Effect of penetrating and blunt ocular trauma on the outcome of traumatic cataract in children in northern India. J Trauma Acute Care Surg 2012; 73:726-30.
http://dx.doi.org/10.1097/TA.0b013e31825eeac9
 
7. Shah MA, Shah SM, Applewar A, et al. OcularTrauma Score: a useful predictor of visual outcome at six weeks in patients with traumatic cataract. Ophthalmology 2012; 119:1336-41.
http://dx.doi.org/10.1016/j.ophtha.2012.01.020
 
8. Khandekar R, Sudhan A, Jain BK, Shrivastav K, Sachan R. Pediatric cataract and surgery outcomes in Central India: a hospital based study. Indian J Med Sci 2007; 61:15-22.
http://dx.doi.org/10.4103/0019-5359.29593
 
9. Kamlesh, Dadeya SS. Management of paediatric traumatic cataract by epilenticular intraocular lens implantation: longterm visual results and postoperative complications. Eye (Lond) 2004; 18:126-30.
http://dx.doi.org/10.1038/sj.eye.6700605
 
10. Johar SR, Savalia NK, Vasavada AR, Gupta PD. Epidemiology based etiological study of paediatric cataracts in western India. Indian J Med Sci 2004; 58:115-21.
PMid:15051906
 
11. Brar GS, Ram J, Pandav SS, et al. Postoperative complications and visual results in uniocular pediatric traumatic cataract. Ophthalmic Surg Lasers 2001; 32:233-8.
PMid:11371091
 
12. Eckstein M, Vijayalakshmi P, Killedar M, Gilbert C, Foster A. Use of intraocular lenses in children with traumatic cataract in South India. Br J Ophthalmol 1998; 82:911-5.
http://dx.doi.org/10.1136/bjo.82.8.911
 
13. Krishnamachary M, Rathi V, Gupta S. Management of traumatic cataract in children. J Cataract Refract Surg 1997; 23 (Suppl 1):681-7.
http://dx.doi.org/10.1016/S0886-3350(97)80054-5
 
14. Gupta AK, Grover AK, Gurha N. Traumatic cataract surgery with intraocular lens implantation in children. J Pediatr Ophthalmol Strabismus 1992; 29:73-8.
PMid:1588479
 
15. Cheema RA, Lukaris AD. Visual recovery in unilateral traumatic pediatric cataracts treated with posterior chamber intraocular lens and anterior vitrectomy in Pakistan. Int Ophthalmol 1999; 23:85-9.
http://dx.doi.org/10.1023/A:1026503413950
 
16. Memon MN, Narsani AK, Nizamani NB. Visual outcome of unilateral traumatic cataract. J Coll Physicians Surg Pak 2012; 22:497-500.
PMid:22868014
 
17. Kumar S, Panda A, Badhu BP, Das H. Safety of primary intraocular lens insertion in unilateral childhood traumatic cataract. JNMA J Nepal Med Assoc 2008; 47:179-85.
PMid:19079390
 
18. Adhikari S, Badhu BP, Bhatta NK, et al. Etiology and clinical profile of pediatric cataract in a tertiary care center of Eastern Nepal. JNMA J Nepal Med Assoc 2007; 46:94-8.
PMid:18274562
 
19. Wilson ME, Hennig A, Trivedi RH, Thomas BJ, Singh SK. Clinical characteristics and early postoperative outcomes of pediatric cataract surgery with IOL implantation from Lahan, Nepal. J Pediatr Ophthalmol Strabismus 2011; 48:286-91.
http://dx.doi.org/10.3928/01913913-20100920-03
 
20. Hyun DW, Lee TG, Cho SW. Unilateral scleral fixation of posterior chamber intraocular lenses in pediatric complicated traumatic cataract. Korean J Ophthalmol 2009; 23:148-52.
http://dx.doi.org/10.3341/kjo.2009.23.3.148

Intra-articular glucocorticoid injections in patients with juvenile idiopathic arthritis in a Singapore hospital

Share this Article

Singapore Med J 2014; 55(5): 248-252; http://dx.doi.org/10.11622/smedj.2014066
Intra-articular glucocorticoid injections in patients with juvenile idiopathic arthritis in a Singapore hospital

Leow OM, Lim LK, Ooi PL, Shek LP, Ang EY, Son MB
Correspondence: Dr Mary Beth Son, marybethson@gmail.com

ABSTRACT
INTRODUCTION This study aimed to evaluate the efficacy and safety of intra-articular glucocorticoid (IAG) injections in our institution in children with juvenile idiopathic arthritis (JIA).
METHODS This is a retrospective assessment of IAG injections performed by the Department of Paediatrics, National University Hospital, Singapore, from October 2009 to October 2011. A total of 26 procedures were evaluated for efficacy, considering parameters such as clinical response, changes in systemic medication, length of time between repeat injections, safety, consent-taking, pre- and post-procedural advice, compliance with aseptic technique, and post-procedural complications.
RESULTS A total of 26 IAG injections of triamcinolone hexacetonide were administered over 17 occasions (i.e. patient encounters) to ten patients with JIA during the study period. After the injections, clinical scoring by a paediatric rheumatologist showed overall improvement by an average of 2.62 points out of 15. Besides six patient encounters that had an increase in systemic medication on the day of the injection, five required an increase within six months post injection, two required no adjustments, and one resulted in a decrease in medications. In all, 21 injections did not require subsequent injections. The mean interval between repeat injections was 7.8 months. Cutaneous side effects were noted in three anatomically difficult joints. Medical documentation with regard to patient progress was found to be lacking.
CONCLUSION As per the recommendations of the American College of Rheumatology, we safely used IAG injections as the first-line therapy in our group of patients with oligoarticular JIA, and/or as an adjunct to systemic therapy in our patients with JIA.

Keywords: complications, efficacy, intra-articular injections, juvenile idiopathic arthritis, safety
Singapore Med J 2014; 55(5): 248-252; http://dx.doi.org/10.11622/smedj.2014066

REFERENCES

1. Wu EY, Van Mater HA, Rabinovich CE. Juvenile Idiopathic Arthritis. In: Kliegman RM, Stanton BF, St. Geme III JW et al, eds. Nelson Textbook of Pediatrics, 19th ed. Philadelphia: Saunders, 2011: 829-39.
http://dx.doi.org/10.1016/B978-1-4377-0755-7.00149-4
 
2. Petty RE, Southwood TR, Baum J, et al. Revision of the proposed classification criteria for juvenile idiopathic arthritis. J Rheumatol 1998; 25:1991-4.
PMid:9779856
 
3. See Y, Koh ET, Boey ML. One hundred and seventy cases of childhood-onset rheumatological disease in Singapore. Ann Acad Med Singapore 1998; 27:496-502.
PMid:9791653
 
4. Arkachaisri T. Pediatric rheumatology in Southeast Asia: insights from the Singapore experience. Curr Rheumatol Rep 2011; 13:117-22.
http://dx.doi.org/10.1007/s11926-010-0159-1
 
5. Beukelman T, Patkar NM, Saag KG, et al. American College of Rheumatology 2011 Recommendations for the Treatment of Juvenile Idiopathic Arthritis. Initiation and Safety Monitoring of Therapeutic Agents for the Treatment of Arthritis and Systemic Features. Clinician's guide.
 
6. See Y. Intra-synovial corticosteroid injections in juvenile chronic arthritis--a review. Ann Acad Med Singapore 1998; 27:105-11.
PMid:9588284
 
7. Sherry DD, Stein LD, Reed AM, Schanberg LE, Kredich DW. Prevention of leg length discrepancy in young children with pauciarticular juvenile rheumatoid arthritis by treatment with intraarticular steroids. Arthritis Rheum 1999; 42:2330-4.
http://dx.doi.org/10.1002/1529-0131(199911)42:11<2330::AID-ANR11>3.0.CO;2-B
 
8. Lepore L, Del Santo M, Malorgio C, et al. Treatment of juvenile idiopathic arthritis with intra-articular triamcinolone hexacetonide: evaluation of clinical effectiveness correlated with circulating ANA and T gamma/delta+ and B CD5+ lymphocyte populations of synovial fluid. Clin Exp Rheumatol 2002; 20:719-22.
PMid:12412208
 
9. Huppertz HI, Tschammler A, Horwitz AE, Schwab KO. Intraarticular corticosteroids for chronic arthritis in children: efficacy and effects on cartilage and growth. J Pediatr 1995; 127:317-21.
http://dx.doi.org/10.1016/S0022-3476(95)70320-9
 
10. Honkanen VE, Rautonen JK, Pelkonen PM. Intra-articular glucocorticoids in early juvenile chronic arthritis. Acta Paediatr 1993; 82:1072-4.
http://dx.doi.org/10.1111/j.1651-2227.1993.tb12815.x
 
11. Zulian F, Martini G, Gobber D, et al. Triamcinolone acetonide and hexacetonide intra-articular treatment of symmetrical joints in juvenile idiopathic arthritis: a double-blind trial. Rheumatology (Oxford) 2004; 43:1288-91.
http://dx.doi.org/10.1093/rheumatology/keh313
 
12. Charalambous CP, Tryfonidis M, Sadiq S, Hirst P, Paul A. Septic arthritis following intra-articular steroid injection of the knee--a survey of current practice regarding antiseptic technique used during intra-articular steroid injection of the knee. Clin Rheumatol 2003; 22:386-90.
http://dx.doi.org/10.1007/s10067-003-0757-7
 
13. Chakravarty K, Pharoah PD, Scott DG. A randomized controlled study of post-injection rest following intra-articular steroid therapy for knee synovitis. Br J Rheumatol 1994; 33:464-8.
http://dx.doi.org/10.1093/rheumatology/33.5.464
 
14. Weitoft T, Rönnblom L. Randomised controlled study of postinjection immobilisation after intra-articular glucocorticoid treatment for wrist synovitis. Ann Rheum Dis 2003; 62:1013-5.
http://dx.doi.org/10.1136/ard.62.10.1013
 
15. Weitoft T, Forsberg C. Importance of immobilization after intraarticular glucocorticoid treatment for elbow synovitis: a randomized controlled study. Arthritis Care Res (Hoboken) 2010; 62:735-7.
http://dx.doi.org/10.1002/acr.20039
 
16. Dernis E, Ruyssen-Witrand A, Mouterde G, et al. Use of glucocorticoids in rheumatoid arthritis - pratical modalities of glucocorticoid therapy: recommendations for clinical practice based on data from the literature and expert opinion. Joint Bone Spine 2010; 77:451-7.
http://dx.doi.org/10.1016/j.jbspin.2009.12.010
 
17. Habib GS, Saliba W, Nashashibi M. Local effects of intra-articular corticosteroids. Clin Rheumatol 2010; 29:347-56.
http://dx.doi.org/10.1007/s10067-009-1357-y
 
18. Lanni S, Bertamino M, Consolaro A, et al. Outcome and predicting factors of single and multiple intra-articular corticosteroid injections in children with juvenile idiopathic arthritis. Rheumatology (Oxford) 2011; 50:1627-34.
http://dx.doi.org/10.1093/rheumatology/ker165
 
19. Job-Deslandre C, Menkes CJ. Complications of intra-articular injections of triamcinolone hexacetonide in chronic arthritis in children. Clin Exp Rheumatol 1990; 8:413-6.
PMid:2397629
 
20. Hunter JA, Blyth TH. A risk-benefit assessment of intra-articular corticosteroids in rheumatic disorders. Drug Saf 1999; 21:353-65.
http://dx.doi.org/10.2165/00002018-199921050-00002
 
21. Pal B, Morris J. Perceived risks of joint infection following intra-articular corticosteroid injections: a survey of rheumatologists. Clin Rheumatol 1999; 18:264-5.
http://dx.doi.org/10.1007/s100670050098
 
22. Geirsson AJ, Statkevicius S, Víkingsson A. Septic arthritis in Iceland 1990-2002: increasing incidence due to iatrogenic infections. Ann Rheum Dis 2008; 67:638-43.
http://dx.doi.org/10.1136/ard.2007.077131
 
23. Breit W, Frosch M, Meyer U, Heinecke A, Ganser G. A subgroup-specific evaluation of the efficacy of intraarticular triamcinolone hexacetonide in juvenile chronic arthritis. J Rheumatol 2000; 27:2696-702.
PMid:11093456
 
24. Neidel J, Boehnke M, Küster RM. The efficacy and safety of intraarticular corticosteroid therapy for coxitis in juvenile rheumatoid arthritis. Arthritis Rheum 2002; 46:1620-8.
http://dx.doi.org/10.1002/art.10313
 
25. Beukelman T, Patkar NM, Saag KG, et al. 2011 American College of Rheumatology recommendations for the treatment of juvenile idiopathic arthritis: initiation and safety monitoring of therapeutic agents for the treatment of arthritis and systemic features. Arthritis Care Res (Hoboken) 2011; 63:465-82.
http://dx.doi.org/10.1002/acr.20460
 
26. Hetland ML, Østergaard M, Ejbjerg B, et al. Short- and long-term efficacy of intra-articular injections with betamethasone as part of a treat-to-target strategy in early rheumatoid arthritis: impact of joint area,repeated injections, MRI findings, anti-CCP, IgM-RF and CRP. Ann Rheum Dis 2012; 71:851-6.
http://dx.doi.org/10.1136/annrheumdis-2011-200632
 
27. Cahill AM, Cho SS, Baskin KM, et al. Benefit of fluoroscopically guided intraarticular, long-acting corticosteroid injection for subtalar arthritis in juvenile idiopathic arthritis. Pediatr Radiol 2007; 37:544-8.
http://dx.doi.org/10.1007/s00247-007-0457-6
 
28. Laurell L, Court-Payen M, Nielsen S, Zak M, Fasth A. Ultrasonography and color Doppler in juvenile idiopathic arthritis: diagnosis and follow-up of ultrasound-guided steroid injection in the wrist region. A descriptive interventional study. Pediatr Rheumatol Online J 2012; 10:11.
http://dx.doi.org/10.1186/1546-0096-10-11

Addition of clonidine or lignocaine to ropivacaine for supraclavicular brachial plexus block: a comparative study

Share this Article

Singapore Med J 2014; 55(4): 229-232; http://dx.doi.org/10.11622/smedj.2014057
Addition of clonidine or lignocaine to ropivacaine for supraclavicular brachial plexus block: a comparative study

Bhatia R, Payal YS, Khurana G
Correspondence: Dr Y S Payal, dryspayal05@gmail.com

ABSTRACT
INTRODUCTION Clonidine is used with local anaesthetics to improve analgesia. However, the improvement conferred when clonidine is used together with ropivacaine is controversial. Thus, the present study aimed to evaluate the improvement in analgesia when clonidine is used together with ropivacaine for supraclavicular brachial plexus block.
METHODS This was a prospective, randomised, double-blind controlled study. A total of 75 patients who were scheduled to undergo supraclavicular block were randomly assigned into three groups (i.e. clonidine, lignocaine and control groups) of 25. Patients in all three groups received 20 mL of 0.75% ropivacaine. In addition to that, patients in the clonidine group received 1 mL of clonidine (150 μg) plus 9 mL of saline, patients in the lignocaine group received 10 mL of 2% lignocaine with adrenaline (1:200,000), and patients in the control group received 10 mL of saline. The characteristics of anaesthesia and analgesia for these three groups were assessed. 
RESULTS The addition of 2% lignocaine with adrenaline to ropivacaine led to earlier onset of the sensory block (by 4.88 mins), but no increase in the duration of analgesia when compared to analgesia using ropivacaine alone. The addition of clonidine to ropivacaine led to earlier onset of sensory and motor blocks (by 2.88 mins and 3.28 mins, respectively), as well as an increased duration of sensory and motor blocks (by 222.64 mins and 192.92 mins, respectively) when compared to analgesia using ropivacaine alone. The total duration of analgesia was increased by 208.24 mins with clonidine when compared to analgesia using ropivacaine alone. There were no significant differences in sedation score and no side effects in all three groups.
CONCLUSION When compared to the use of ropivacaine alone, the addition of 150 μg clonidine to ropivacaine for brachial plexus block achieved earlier analgesic onset and improved duration of analgesia, without unwanted side effects.

Keywords: anaesthetic technique, clonidine, duration of analgesia, ropivacaine, supraclavicular brachial plexus block
Singapore Med J 2014; 55(4): 229-232; http://dx.doi.org/10.11622/smedj.2014057

REFERENCES

1. Pöpping DM, Elia N, Marret E, Wenk M, Tramèr MR. Clonidine as an adjuvant to local anesthetics for peripheral nerve and plexus blocks: a meta-analysis of randomized trials Anesthesiology 2009; 111:406-15.
http://dx.doi.org/10.1097/ALN.0b013e3181aae897
 
2. McCartney CJ, Duggan E, Apatu E. Should we add clonidine to local anesthetic for peripheral nerve blockade? A qualitative systematic review of the literature. Reg Anesth Pain Med 2007; 32:330-8.
 
3. Duma A, Urbanek B, Sitzwohl C, et al. Clonidine as an adjuvant to local anaesthetic axillary brachial plexus block: a randomized, controlled study. Br J Anaesth 2005; 94:112-6.
http://dx.doi.org/10.1093/bja/aei009
 
4. Erlacher W, Schuschnig C, Koinig H, et al. Clonidine as adjuvant for mepivacaine, ropivacaine and bupivacaine in axillary, perivascular brachial plexus block. Can J Anaesth 2001; 48:522-5.
http://dx.doi.org/10.1007/BF03016825
 
5. Esteves S, Sá P, Figueiredo D, Pèrez Souto A. [Duration and quality of postoperative analgesia after brachial plexus block for shoulder surgery: ropivacaine 0.5% versus ropivacaine 0.5% plus clonidine]. Rev Esp Anestesiol Reanim 2002; 49:302-5. Spanish.
 
6. Moore DC, Bridenbaugh LD, Eather KF. Block of the upper extremity. Arch Surg 1965; 90:68-72.
http://dx.doi.org/10.1001/archsurg.1965.01320070070015
 
7. Franco CD. Manual of regional anesthesia [online]. Available from http://www.cookcountyregional.com/Chapter6.pdf. Accessed July 26, 2013.
 
8. Wakhlo R, Gupta V, Raina A, Gupta SD, Lahori VU. Supraclavicular Plexus Block: Effect of Adding Tramadol or Butorphanol as an Adjuncts to Local Anaesthetic on Motor and Sensory Block and duration of Post-operative Analgesia. J Anaesth Clin Pharmacol 2009; 25:17-20.
 
9. Cline E, Franz D, Polley RD, et al. Analgesia and effectiveness of levobupivacaine compared with ropivacaine in patients undergoing an axillary brachial plexus block. AANA Journal 2004; 72:339-45.
 
10. Singh SP, Singh V, Kaushal D, Jafa S. Effect of alkalinized bupivacaine and fentanyl mixture in supraclavicular brachial plexus block-A randomised double blind controlled trial. J Anaesth Clin Pharmacol 2009; 25:25-8.
 
11. El Saied AH, Steyn MP, Ansermino JM. Clonidine prolongs the effect of ropivacaine for axillary brachial plexus blockade. Can J Anaesth 2000; 47:9 6 2- 7.
 
12. Eledjam JJ, Deschodt J, Viel EJ, et al. Brachial plexus block with bupivacaine: effects of added alpha-adrenergic agonists: comparison between clonidine and epinephrine. Can J Anaesth 1991; 38:870-5.
http://dx.doi.org/10.1007/BF03036962
 
13. Ishiyama T, Dohi S, Iida H. The vascular effects of topical and intravenous alpha2-adrenoceptor agonist clonidine on canine pial microcirculation. Anesth Analg 1998; 86:766-72.
 
14. McClure JH. Ropivacaine – review. Br J Anaesth 1996; 76:300-7.
http://dx.doi.org/10.1093/bja/76.2.300
 
15. Gaumann DM, Brunet PC, Jirounek P. Clonidine enhances the effects of lidocaine on C-fiber action potential. Anesth Analg 1992; 74:719-25.
http://dx.doi.org/10.1213/00000539-199205000-00017
 
16. Butterworth JF 5th, Strichartz GR. The alpha 2-adrenergic agonists clonidine and guanfacine produce tonic and phasic block of conduction in rat sciatic nerve fibers. Anesth Analg 1993; 76:295-301.
 
17. Casati A, Fanelli G, Aldegheri G, Berti M, Colnaghi E, Cedrati V. Interscalene brachial plexus anaesthesia with 0.5%, 0.75% or 1% ropivacaine: a doubleblind comparison with 2% mepivacaine. Br J Anaesth 1999; 83:872-5.
http://dx.doi.org/10.1093/bja/83.6.872
 
18. Cornish PB, Leaper C. The sheath of the brachial plexus: fact or fiction? Anesthesiology 2006; 105:563-5.
http://dx.doi.org/10.1097/00000542-200609000-00021
 
19. Klaastad Ø, Smedby O, Thompson GE, et al. Distribution of local anesthetic in axillary brachial plexus block: a clinical and magnetic resonance imaging study. Anesthesiology 2002; 96:1315-24.
http://dx.doi.org/10.1097/00000542-200206000-00009
 
20. Singelyn FJ, Gouverneur JM, Robert A. A minimum dose of clonidine added to mepivacaine prolongs the duration of anesthesia and analgesia after axillary brachial plexus block. Anesth Analg 1996; 83:1046-50.
 
21. Iohom G, Machmachi A, Diarra DP, et al. The effects of clonidine added to mepivacaine for paronychia surgery under axillary brachial plexus block. Anesth Analg 2005; 100:1179-83.
http://dx.doi.org/10.1213/01.ANE.0000145239.17477.FC
 
22. Chakraborty S, Chakrabarti J, Mandal MC, Hazra A, Das S. Effect of clonidine as adjuvant in bupivacaine-induced supraclavicular brachial plexus block: A randomized controlled trial. Indian J Pharmacol 2010; 42:74 - 7.
http://dx.doi.org/10.4103/0253-7613.64498
 
23. Hayashi Y, Maze M. Alpha 2 adrenoceptor agonists and anaesthesia. Br J Anaesth 1993; 71:108-18.
http://dx.doi.org/10.1093/bja/71.1.108
 
24. Guo TZ, Jiang JY, Buttermann AE, Maze M. Dexmedetomidine injection into the locus ceruleus produces antinociception. Anesthesiology 1996; 84:873- 81.
http://dx.doi.org/10.1097/00000542-199604000-00015
 
25. Sia S, Lepri A. Clonidine administered as an axillary block does not affect postoperative pain when given as the sole analgesic. Anesth Analg 1999; 88:1109-2.
 
26. Gaumann DM, Brunet PC, Jirounek P. Hyperpolarizing after potentials in C fibers and local anesthetic effects of clonidine and lidocaine. Pharmacology 1994; 48:21-9.
http://dx.doi.org/10.1159/000139158
 
27. Leem JW, Choi Y, Han SM, et al. Conduction block by clonidine is not mediated by alpha2-adrenergic receptors in rat sciatic nerve fibers. Reg Anesth Pain Med 2000; 25:620-5.
 
28. Hutschala D, Mascher H, Schmetterer L, et al. Clonidine added to bupivacaine enhances and prolongs analgesia after brachial plexus block via a local mechanism in healthy volunteers. Eur J Anaesthesiol 2004; 21:198 -204.
http://dx.doi.org/10.1097/00003643-200403000-00006

Age- and gender-related differences in drug utilisation and adverse drug reaction patterns among patients in a coronary care unit

Share this Article

Singapore Med J 2014; 55(4): 221-228; http://dx.doi.org/10.11622/smedj.2014056
Age- and gender-related differences in drug utilisation and adverse drug reaction patterns among patients in a coronary care unit

Kunnoor NS, Devi P, Kamath DY, Anthony N, George J
Correspondence: Dr Nitin S Kunnoor, drnitinskunnoor@yahoo.in

ABSTRACT
INTRODUCTION This study aimed to examine age- and gender-related differences in the comorbidities, drug utilisation and adverse drug reaction (ADR) patterns of patients admitted to a coronary care unit (CCU).
METHODS The present study was a retrospective cohort study. Two trained physicians independently reviewed the case records of CCU patients over a period of one year (Jan–Dec 2008). The demographic, clinical, and drug prescription data of the patients were analysed according to age group (18–59 years vs ≥ 60 years) and gender. 
RESULTS A total of 574 patients were admitted to the CCU during the study period. Of these 574 patients, 65.2% were male, and 48.4% were ≥ 60 years old. No significant gender-based differences were found for the prescription of cardiovascular and non-cardiovascular drugs, and ADR patterns (p > 0.05). Male patients aged ≥ 60 years were found to have a higher rate of polypharmacy than those aged 18–59 years (p = 0.001). The duration of hospital stay was longer in male than female patients (p = 0.008), and the duration of CCU stay was longer for male patients aged ≥ 60 years than males aged 18–59 years (p = 0.013). Compared to patients aged 18–59 years, a greater number of patients aged ≥ 60 years were prescribed cardiovascular (p = 0.006) and non-cardiovascular drugs (p = 0.015). Patients aged ≥ 60 years also had a higher rate of polypharmacy (p = 0.001) and ADRs (p = 0.013), and a longer duration of CCU stay (p = 0.013). Renal (p = 0.047) and cutaneous (p = 0.003) ADRs were found to be more common in patients aged ≥ 60 years. 
CONCLUSION No major gender-related differences were observed in the prescription, drug utilisation and ADR patterns of our study cohort. Higher drug utilisation, ADR rates, and longer duration of CCU stay were noted in patients aged ≥ 60 years.

Keywords: adverse drug reactions, age, coronary care unit, drug utilisation, gender
Singapore Med J 2014; 55(4): 221-228; http://dx.doi.org/10.11622/smedj.2014056

REFERENCES

1. Surveillance of mortality and cardiovascular disease related morbidity in Industrial settings. WHO Country Office for India, Geneva, Switzerland [online]. Available at: www.georgeinstitute.org.au/global-health-landscape/global-health-resourc.... Accessed July 3, 2011.
 
2. Rosamond W, Flegal K, Furie K, et al. Heart disease and stroke statistics--2008 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 2008; 117:e 25 -146.
 
3. Mendelson MA, Hendel RC. Myocardial infarction in women. Cardiology 1995; 86:272-85.
http://dx.doi.org/10.1159/000176891
 
4. Jousilahti P, Vartiainen E, Tuomilehto J, Puska P. Sex, age, cardiovascular risk factors, and coronary heart disease: a prospective follow-up study of 14 786 middle-aged men and women in Finland. Circulation 1999; 99:1165 -72.
http://dx.doi.org/10.1161/01.CIR.99.9.1165
 
5. Anand SS, Islam S, Rosengren A, et al. Risk factors for myocardial infarction in women and men: insights from the INTERHEART study. Eur Heart J 2008; 29:932-40.
http://dx.doi.org/10.1093/eurheartj/ehn018
 
6. Towfighi A, Zheng L, Ovbiagele B. Sex-specific trends in midlife coronary heart disease risk and prevalence. Arch Intern Med 2009; 169:1762-6.
http://dx.doi.org/10.1001/archinternmed.2009.318
 
7. Vulic D, Lee BT, Dede J, Lopez VA, Wong ND. Extent of control of cardiovascular risk factors and adherence to recommended therapies in US multiethnic adults with coronary heart disease: from a 2005-2006 national survey. Am J Cardiovasc Drugs 2010; 10:109-14.
http://dx.doi.org/10.2165/11535240-000000000-00000
 
8. de Ruijter W, de Waal MW, Gussekloo J, Assendelft WJ, Blom JW. Time trends in preventive drug treatment after myocardial infarction in older patients. Br J Gen Pract 2010; 60:47-9.
http://dx.doi.org/10.3399/bjgp10X482103
 
9. Gnavi R, Migliardi A, Demaria M, et al. Statins prescribing for the secondary prevention of ischaemic heart disease in Torino, Italy. A case of ageism and social inequalities. Eur J Public Health 2007; 17:492-6.
http://dx.doi.org/10.1093/eurpub/ckm005
 
10. Ko DT, Mamdani M, Alter DA. Lipid-lowering therapy with statins in highrisk elderly patients: the treatment-risk paradox. JAMA 2004; 291:1864-70.
http://dx.doi.org/10.1001/jama.291.15.1864
 
11. Driscoll A, Beauchamp A, Lyubomirsky G, et al. Suboptimal management of cardiovascular risk factors in coronary heart disease patients in primary care occurs particularly in women. Intern Med J 2011; 41:730-6.
http://dx.doi.org/10.1111/j.1445-5994.2011.02534.x
 
12. Bates DW, Spell N, Cullen DJ, et al. The costs of adverse drug events in hospitalized patients. Adverse Drug Events Prevention Study Group. JAMA 1997; 277:307-11.
http://dx.doi.org/10.1001/jama.1997.03540280045032
 
13. Rademaker M. Do women have more adverse drug reactions? Am J Clin Dermatol 2001; 2:349-51.
http://dx.doi.org/10.2165/00128071-200102060-00001
 
14. Gurwitz JH, Avorn J. The ambiguous relation between aging and adverse drug reactions. Ann Intern Med 1991; 114:956-66.
http://dx.doi.org/10.7326/0003-4819-114-11-956
 
15. Davies EC, Green CF, Mottram DR, Pirmohamed M. Adverse drug reactions in hospitals: a narrative review. Curr Drug Saf 2007; 2:79-87.
http://dx.doi.org/10.2174/157488607779315507
 
16. Mohebbi N, Shalviri G, Salarifar M, Salamzadeh J, Gholami K. Adverse drug reactions induced by cardiovascular drugs in cardiovascular care unit patients. Pharmacoepidemiol Drug Saf 2010; 19:889-94.
http://dx.doi.org/10.1002/pds.1916
 
17. Devi P, Kamath DY, Anthony N, Santosh S, Dias B. Patterns, predictors and preventability of adverse drug reactions in the coronary care unit of a tertiary care hospital. Eur J Clin Pharmacol 2012; 68:427-33.
http://dx.doi.org/10.1007/s00228-011-1138-9
 
18. WHO Collaborating Centre for Drug Statistics Methodology. Guidelines for ATC classification and DDD assignment 2011. Oslo, 2010. 1-8-2012 [online]. Available at: www.whocc.no/filearchive/publications/2011guidelines.pdf. Accessed August 1, 2012.
 
19. World Health Organization. International Classification of Diseases Version 10. 1-8-2012 [online]. Available at: www.apps.who.int/classifications/icd10/browse/2010/en. Accessed August 1, 2012.
 
20. World Health Organization. International drug monitoring- the role of national centres. Technical Report No.498, World Health Organisation, Geneva [online]. Available at: www.who-umc.org/graphics/24756.pdf. Accessed August 1, 2012.
 
21. Blomkalns AL, Chen AY, Hochman JS, et al. Gender disparities in the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes: large-scale observations from the CRUSADE (Can Rapid Risk Stratification of Unstable Angina Patients Suppress Adverse Outcomes With Early Implementation of the American College of Cardiology/American Heart Association Guidelines) National Quality Improvement Initiative. J Am Coll Cardiol 2005; 45:832-7.
http://dx.doi.org/10.1016/j.jacc.2004.11.055
 
22. Stone PH, Thompson B, Anderson HV, et al. Influence of race, sex, and age on management of unstable angina and non-Q-wave myocardial infarction: The TIMI III registry. JAMA 1996; 275:1104-12.
http://dx.doi.org/10.1001/jama.1996.03530380046030
 
23. Shaw LJ, Bugiardini R, Merz CN. Women and ischemic heart disease: evolving knowledge. J Am Coll Cardiol 2009; 54:1561-75.
http://dx.doi.org/10.1016/j.jacc.2009.04.098
 
24. Camici PG, Crea F. Coronary microvascular dysfunction. N Engl J Med 2007; 356:830-40.
http://dx.doi.org/10.1056/NEJMra061889
 
25. Banerjee S, Kumar V, Ramachandran P, Kamath A. Does The Pharmacological Management Of Unstable Angina Vary With Age And Gender – A Descriptive Study. J Clin Diag Res 2010; 4:3150-57.
 
26. Sharma M, Ganguly NK. Premature coronary artery disease in Indians and its associated risk factors. Vasc Health Risk Manag 2005; 1:217-25.
 
27. National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis 2002; 39 (2 suppl 1):S1-266.
http://dx.doi.org/10.1016/S0272-6386(02)70132-7
 
28. National Institute for Health and Clinical Excellence, United Kingdom. Chronic Heart Failure: Management of chronic heart failure in adults in primary and secondary care (Issued: August 2010). Available at: http://www.nice.org.uk/nicemedia/live/13099/50517/50517.pdf. Accessed March 24, 2014.
 
29. National Institute for Health and Care Excellence, United Kingdom. Chronic kidney disease: Early identification and management of chronic kidney disease in adults in primary and secondary care (Issued: September 2008). Available at: http://www.nice.org.uk/nicemedia/live/12069/42117/42117.pdf. Accessed March 24, 2014.
 
30. Xavier D, Pais P, Devereaux PJ, et al. Treatment and outcomes of acute coronary syndromes in India (CREATE): a prospective analysis of registry data. Lancet 2008; 371:1435-42.
http://dx.doi.org/10.1016/S0140-6736(08)60623-6
 
31. Tepper D. Frontiers in congestive heart failure: Effect of Metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Congest Heart Fail 1999; 5:184-5.
 
32. Packer M, Coats AJ, Fowler MB, et al. Effect of carvedilol on survival in severe chronic heart failure. N Engl J Med 2001; 344:1651-8.
http://dx.doi.org/10.1056/NEJM200105313442201
 
33. Hunt SA, Abraham WT, Chin MH, et al. 2009 focused update incor porated into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: developed in collaboration with the International Society for Heart and Lung Transplantation. Circulation 2009; 119:e391-e479.
http://dx.doi.org/10.1161/CIRCULATIONAHA.109.192065
 
34. Marandi T, Baburin A, Ainla T. Use of evidence-based pharmacotherapy after myocardial infarction in Estonia. BMC Public Health 2010; 10:358.
http://dx.doi.org/10.1186/1471-2458-10-358
 
35. Ghosh A, Das AK, Pramanik S, Saha UK. Drug utilization study in patients of acute coronary syndrome on follow-up visits at a tertiary care centre In Kolkata. Asian J Pharm Life Sci 2013; 2:155-65.
 
36. Verkerk AO, Wilders R, Veldkamp MW, et al. Gender disparities in cardiac cellular electrophysiology and arrhythmia susceptibility in human failing ventricular myocytes. Int Heart J 2005; 46:1105-18.
http://dx.doi.org/10.1536/ihj.46.1105
 
37. Krause T, Lovibond K, Caulfield M, McCormack T, Williams B. Management of hypertension: summary of NICE guidance. BMJ 2011; 343:d4891.
http://dx.doi.org/10.1136/bmj.d4891
 
38. Zaitune MP, Barros MB, Cesar CL, Carandina L, Goldbaum M. [Arterial hypertension in the elderly: prevalence, associated factors, and control practices in Campinas, Sao Paulo, Brazil]. Cad Saude Publica 2006; 22:285-94. Portuguese.
http://dx.doi.org/10.1590/S0102-311X2006000200006
 
39. Suominen-Taipale AL, Martelin T, Koskinen S, Holmen J, Johnsen R. Gender differences in health care use among the elderly population in areas of Norway and Finland. A cross-sectional analysis based on the HUNT study and the FINRISK Senior Survey. BMC Health Serv Res 2006; 6:110
http://dx.doi.org/10.1186/1472-6963-6-110
 
40. Davies EC, Green CF, Mottram DR, Pirmohamed M. Adverse drug reactions in hospitals: a narrative review. Curr Drug Saf 2007; 2:79-87.
http://dx.doi.org/10.2174/157488607779315507
 
41. Domecq C, Naranjo CA, Ruiz I, Busto U. Sex-related variations in the frequency and characteristics of adverse drug reactions. Int J Clin Pharmacol Ther Toxicol 1980; 18:362-6.
 
42. Karimzadeh I, Namazi S, Shalviri G, Gholami K. Cardiovascular drug adverse reactions in hospitalized patients in cardiac care unit. African J Pharm Pharmacol 2011; 5:493-9.
http://dx.doi.org/10.5897/AJPP10.413
 
43. Routledge PA, O'Mahony MS, Woodhouse KW. Adverse drug reactions in elderly patients. Br J Clin Pharmacol 2004; 57:121-6.
http://dx.doi.org/10.1046/j.1365-2125.2003.01875.x

Clinical characteristics and treatment outcomes of patients with Brugada syndrome in northeastern Thailand

Share this Article

Singapore Med J2014; 55(4): 217-220; http://dx.doi.org/10.11622/smedj.2014055
Clinical characteristics and treatment outcomes of patients with Brugada syndrome in northeastern Thailand

Makarawate P, Chaosuwannakit N, Vannaprasaht S, Tassaneeyakul W, Sawanyawisuth K
Correspondence: Dr Kittisak Sawanyawisuth, kittisak@kku.ac.th

ABSTRACT
INTRODUCTION Brugada syndrome (BrS) is a common genetic cause of sudden cardiac arrest (SCA) due to polymorphic ventricular tachycardia and ventricular fibrillation. The current recommended therapy for high-risk BrS patients is the use of an implantable cardioverter defibrillator (ICD). The present study aimed to report the clinical characteristics and treatment outcomes of BrS patients in northeastern Thailand.
METHODS Patients who were diagnosed with BrS or had a Brugada electrocardiogram (ECG) between 2005 and 2012 at Khon Kaen University’s hospitals were enrolled in the present study. Patients’ clinical characteristics, ECG type, laboratory results and treatment were reviewed. 
RESULTS A total of 90 eligible patients were enrolled. Of these, 79 (87.8%) patients were symptomatic – 65 (82.3%) had documented SCA and 14 (17.7%) had unexplained syncope. The remaining 11 (12.2%) patients were asymptomatic with Brugada ECG. A majority of the patients enrolled were born in northeastern Thailand. The mean age of the symptomatic patients was 44.49 ± 8.55 years. Among the symptomatic patients, a majority were male (n = 77, 97.5%) and 23 (29.1%) patients had a family history of SCA. Almost all BrS patients who were symptomatic (96.2%) received ICD treatment for secondary prevention. The number of patients who received appropriate ICD therapy was 4.2 times of those who received inappropriate shocks. Only 3 (3.8%) symptomatic BrS patients refused ICD treatment.
CONCLUSION Clinical characteristics did not distinguish between symptomatic BrS patients and asymptomatic patients with Brugada ECGs. The clinical characteristics and treatment outcomes for the symptomatic BrS patients with SCA and unexplained syncope were similar. Among the BrS patients implanted with secondary prevention ICD in Northeastern Thailand, nearly one-third had received appropriate ICD therapy, far exceeding the incidence of device-related complications and inappropriate therapy.

Keywords: Brugada syndrome, implantable cardioverter defibrillator, outcomes, treatment
Singapore Med J2014; 55(4): 217-220; http://dx.doi.org/10.11622/smedj.2014055

REFERENCES

1. Tatsanavivat P, Chirawatkul A, Klungboonkrong V, et al. Sudden and unexplained deaths in sleep (Laitai) of young men in rural northeastern Thailand. Int J Epidemiol 1992; 21:904-10.
http://dx.doi.org/10.1093/ije/21.5.904
 
2. Sung RJ, Kuo CT, Wu SN, et al. Sudden cardiac death syndrome: age, gender, ethnicity and genetics. Acta Cardiol Sin 2008; 24:65-74.
 
3. Nademanee K, Veerakul K, Nimmannit S, et al. Arrhythmogenic marker for the sudden unexplained death syndrome in Thai men. Circulation 1997; 96:2595-600.
http://dx.doi.org/10.1161/01.CIR.96.8.2595
 
4. Gussak I, Antzelevitch C, Bjerregaard P, Towbin JA, Chaitman BR. The Brugada syndrome: clinical, electrophysiologic and genetic aspects. J Am Coll Cardiol 1999; 33:5-15.
http://dx.doi.org/10.1016/S0735-1097(98)00528-2
 
5. Sangwatanaroj S, Prechawat S, Sunsaneewitayakul B, et al. Right ventricular electrocardiographic leads for detection of Brugada syndrome in sudden unexplained death syndrome survivors and their relatives. Clin Cardiol 2001; 24:776-81.
http://dx.doi.org/10.1002/clc.4960241205
 
6. Makarawate P, Sangwatanaroj S. Effect of high glycemic index diets on ST segment elevation in Brugada syndrome. Asean Heart J 2008; 15:57-62.
 
7. Sangwatanaroj S, Prechawat S, Sunsaneewitayakul B, et al. New electrocardiographic leads and the procainamide test for the detection of the Brugada sign in sudden unexplained death syndrome survivors and their relatives. Eur Heart J 2001; 22:2290-6.
http://dx.doi.org/10.1053/euhj.2001.2691
 
8. Nademanee K, Veerakul G, Mower M, et al. Defibrillator versus beta blockers for unexplained death in Thailand (DEBUT): a randomized clinical trial. Circulation 2003; 107:2221-6.
http://dx.doi.org/10.1161/01.CIR.0000066319.56234.C8
 
9. Brugada J, Brugada R, Brugada P. Pharmacological and device approach to therapy of inherited cardiac disease associated with cardiac arrhythmias and sudden death. J Electrocardiol 2000; 33 suppl 1:41-7.
http://dx.doi.org/10.1054/jelc.2000.20322
 
10. Antzelevitch C. Brugada syndrome. Pacing Clin Electrophysiol 2006; 29:1130 -59.
http://dx.doi.org/10.1111/j.1540-8159.2006.00507.x
 
11. Brugada P, Benito B, Brugada R, Brugada J. Brugada syndrome: update 2009. Hellenic J Cardiol 2009; 50:352-72.
 
12. Berne P, Brugada J. Brugada syndrome 2012. Circulation 2012; 76:1563-71.
http://dx.doi.org/10.1253/circj.CJ-12-0717
 
13. Sarkozy A, Sorgente A, Boussy T, et al. The value of family history of sudden death in patients with diagnosis type 1 Brugada ECG pattern. Eur Heart J 2011; 32:2153-60.
http://dx.doi.org/10.1093/eurheartj/ehr129
 
14. Sacher F, Probst V, Iesaka Y, et al. Outcome after implantation of a cardioverter-defibrillator in patients with Brugada syndrome: a multicenter study. Circulation 2006; 114:2317-24.
http://dx.doi.org/10.1161/CIRCULATIONAHA.106.628537

The association of cardiovascular disease with impaired health-related quality of life among patients with type 2 diabetes mellitus

Share this Article

Singapore Med J 2014; 55(4): 209-216; http://dx.doi.org/10.11622/smedj.2014054
The association of cardiovascular disease with impaired health-related quality of life among patients with type 2 diabetes mellitus

Tan MC, Ng OC, Wong TW, Hejar AR, Anthony J, Sintonen H
Correspondence: Ms Mun Chieng Tan, mun_chieng_tan@yahoo.com

ABSTRACT
INTRODUCTION The aim of this study was to evaluate the health-related quality of life (HRQoL) of Malaysian patients with type 2 diabetes mellitus (T2DM) who have cardiovascular disease (CVD), as well as identify the determinants of HRQoL among this cohort of patients.
METHODS This study was an analytical cross-sectional study involving 313 patients aged 30–78 years (150 men, 163 women; mean age 55.7 ± 9.2 years) who were diagnosed with T2DM (mean duration of T2DM 10.1 ± 8.1 years) at two tertiary Malaysian government hospitals. The patients’ sociodemographic, lifestyle, clinical and laboratory data were collected prospectively from medical records and via face-to-face interviews. HRQoL was assessed using the 15D instrument – a generic, 15-dimensional and standardised measure of HRQoL that can be used as both a profile and a single index score measure. 
RESULTS T2DM patients with CVD were found to have significantly lower 15D HRQoL scores than their nonCVD counterparts (p < 0.001). The HRQoL of T2DM patients with CVD was significantly lower than those without CVD (p < 0.05) in all of the 15 dimensions of the 15D instrument. Multinomial logistic regression analysis using backward stepwise method revealed a significant association between CVD and impaired HRQoL (odds ratio [OR] 11.746, 95% confidence interval [CI] 4.898–28.167). Age (OR 1.095, 95% CI 1.054–1.137), duration of T2DM (OR 1.085, 95% CI 1.032–1.140), ethnicity (OR 0.411, 95% CI 0.187–0.903), body mass index (OR 1.074, 95% CI 1.006–1.148), and physical activity level (OR 3.506, 95% CI 1.415–8.689) were also significant predictors of HRQoL.
CONCLUSION In T2DM patients, the presence of CVD was significantly associated with a lower HRQoL. Therefore, the importance of tertiary prevention to minimise the potential deterioration of the HRQoL of T2DM patients with CVD should be highly emphasised.

Keywords: 15D instrument, cardiovascular disease, health-related quality of life, type 2 diabetes mellitus
Singapore Med J 2014; 55(4): 209-216; http://dx.doi.org/10.11622/smedj.2014054

REFERENCES

1. International Diabetes Federation. IDF Diabetes Atlas. 5th ed. Brussels, Belgium: IDF, 2011.
 
2. Hahl J, Hämäläinen H, Sintonen H, et al. Health-related quality of life in type 1 diabetes without or with symptoms of long-term complications. Qual Life Res 2002; 11:427-36.
http://dx.doi.org/10.1023/A:1015684100227
 
3. Haffner SM, Letho S, Rönnemaa T, Pyörälä K, Laakso M. Mortality from coronary heart disease in subject with type 2 diabetes and in non diabetic subjects with and without prior myocardial infarction. N Engl J Med 1998; 339:229-34.
http://dx.doi.org/10.1056/NEJM199807233390404
 
4. Diabetes Drafting Group. Prevalence of small vessel and large vessel disease in diabetic patients from 14 centres: The World Health Organization Multinational Study of Vascular Disease in Diabetics. Diabetologia 1985; 28:615- 40.
http://dx.doi.org/10.1007/BF00290267
 
5. Assmann G, Schulte H. The Prospective Cardiovascular Münster (PROCAM) study: Prevalence of hyperlipidemia in persons with hypertension and/or diabetes mellitus and the relationship to coronary heart disease. Am Heart J 1988; 116:1713-24.
http://dx.doi.org/10.1016/0002-8703(88)90220-7
 
6. Stamler J, Vaccaro O, Neaton JD, Wentworth D. Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. Diabetes Care 1993;16:434-44.
http://dx.doi.org/10.2337/diacare.16.2.434
 
7. Gu K, Cowie CC, Harris MI. Diabetes and decline in heart disease mortality in US adults. JAMA 1999; 281:1291-7.
http://dx.doi.org/10.1001/jama.281.14.1291
 
8. Fox CS. Cardiovascular disease risk factors, type 2 diabetes mellitus, and the Framingham Heart Study. Trends Cardiovas Med 2010; 20:90-5.
http://dx.doi.org/10.1016/j.tcm.2010.08.001
 
9. Fisher M, McMurray JJ. Diabetic cardiology. London: John Wiley & Sons, 20 07.
 
10. American Heart Association. Heart Disease and Stroke Statistics: 2009 Update. Dallas: American Heart Association, 2009.
 
11. Stern MP. Glycemia and cardiovascular risk. Diabetes Care 1997; 20:1501-2.
 
12. Laakso M. Hyperglycemia and cardiovascular disease in type 2 diabetes. Diabetes 1999; 48:937-42.
http://dx.doi.org/10.2337/diabetes.48.5.937
 
13. Morrish NJ, Wang SL, Stevens LK, Fuller JH, Keen K. Mortality and causes of death in the WHO multinational study of vascular disease in diabetes. Diabetologia 2001; 44 Suppl 2:S14-21.
http://dx.doi.org/10.1007/PL00002934
 
14. Lloyd A, Sawyer W, Hopkinson P. Impact of long-term complications on quality of life in patients with type 2 diabetes not using insulin. Value Health 2001; 4:392-400.
http://dx.doi.org/10.1046/j.1524-4733.2001.45029.x
 
15. The Criteria Committee of the New York Heart Association. Nomenclature and criteria of diseases of the heart and blood vessels. Boston: Little, Brown and company, 1973.
 
16. Kaplan RM. Health-related quality of life in cardiovascular disease.J Consult Clin Psychol 1988; 56:382-92.
http://dx.doi.org/10.1037/0022-006X.56.3.382
 
17. Sintonen H. The 15D instrument of health-related quality of life: Properties and applications. Ann Med 2001; 33:328-36.
http://dx.doi.org/10.3109/07853890109002086
 
18. Lee RD, Nieman DC. Nutritional Assessment. 5th ed. New York: McGrawHill Higher Education, 2010.
 
19. International Physical Activity Questionnaire Research Committee. Guidelines for Data Processing and Analysis of the International Physical Activity Questionnaire (IPAQ). November 2005. Available at: www.ipaq.ki.se. Accessed August 1, 2011.
 
20. World Health Organization. Health topics. Reproductive health. Available at: www.who.int/topics/reproductive_health/en. Accessed September 1, 2011.
 
21. Sintonen H. Outcome measurements in acid-related diseases. Pharmacoeconomics 1994; 5:17-26.
http://dx.doi.org/10.2165/00019053-199400053-00005
 
22. Sintonen H. The 15D-measure of health-related quality of life. I. Reliability, validity and sensitivity of its health state descriptive system. Working Paper 41. Melbourne: National Centre for Health Program Evaluation, 1994.
 
23. Sintonen H. The 15D-measure of health-related quality of life. II. Feasibility, reliability and validity of its valuation system. Working Paper 42. Melbourne: National Centre for Health Program Evaluation, 1995.
 
24. Testa MA, Simonson DC. Assessment of quality-of-life outcomes. N Engl J Med 1996; 334:835-40.
http://dx.doi.org/10.1056/NEJM199603283341306
 
25. Rubin RR, Peyrot M. Quality of life and diabetes. Diabetes Metab Res Rev 1999; 15:205-18.
http://dx.doi.org/10.1002/(SICI)1520-7560(199905/06)15:3<205::AID-DMRR29>3.0.CO;2-O
 
26. Wändell PE, Brorsson B, Åberg H. Functioning and well-being of patients with type 2 diabetes or angina pectoris, compared with the general population. Diabetes Metab 2000; 26:465-71.
 
27. Unsar S, Sut N, Durna Z. Health-related quality of life in patients with coronary artery disease. J Cardiovasc Nurs 2007; 22:501-7.
http://dx.doi.org/10.1097/01.JCN.0000297382.91131.8d
 
28. Stafford M, Soljak M, Pledge V, Mindell J. Socio-economic differences in the health-related quality of life impact of cardiovascular conditions. Eur J Public Health 2012; 22:301-5.
http://dx.doi.org/10.1093/eurpub/ckr007
 
29. Li C, Ford ES, Mokdad AH, et al. Clustering of cardiovascular disease risk factors and health-related quality of life among US adults. Value Health 2008; 11:689-99.
http://dx.doi.org/10.1111/j.1524-4733.2007.00307.x
 
30. Ahola AJ, Saraheimo M, Forsblom C, et al. Health-related quality of life in patients with type 1 diabetes-association with diabetic complications (The FinDiane Study). Nephrol Dial Transplant 2010; 25:1903-8.
http://dx.doi.org/10.1093/ndt/gfp709
 
31. Akinci F1, Yildirim A, Gözü H, et al. Assessment of health-related quality of life (HRQoL) of patients with type 2 diabetes in Turkey. Diabetes Res Clin Pract 2008; 79:117-23.
http://dx.doi.org/10.1016/j.diabres.2007.07.003
 
32. Hänninen J, Takala J, Keinänen-Kiukaanniemi S. Quality of life in NIDDM patients assessed with the SF-20 questionnaire. Diabetes Res Clin Pract 1998; 42:17-27.
http://dx.doi.org/10.1016/S0168-8227(98)00085-0
 
33. Papadopoulos AA, Kontodimopoulos N, Frydas A, Ikonomakis E, Niakas D. Predictors of health-related quality of life in type II diabetic patients in Greece. BMC Public Health 2007; 7:186.
http://dx.doi.org/10.1186/1471-2458-7-186
 
34. Järvinena O, Saarinen T, Julkunen J, Huhtala H, Tarkka MR. Changes in health-related quality of life and functional capacity following coronary artery bypass graft surgery. Eur J Cardiothorac Surg 2003; 24:750-6.
http://dx.doi.org/10.1016/S1010-7940(03)00413-5
 
35. Fischbacher CM, Hunt S, Alexander L. How physically active are South Asians in the United Kingdom? A literature review. J Public Health (Oxf) 2004; 26:250-8.
http://dx.doi.org/10.1093/pubmed/fdh158
 
36. Miettola J, Niskanen LK, Viinamaki H, Sintonen H, Kumpusalo E. Metabolic syndrome is associated with impaired health-related quality of life: Lapinlahti 2005 study. Qual Life Res 2008; 17:1055-62.
http://dx.doi.org/10.1007/s11136-008-9386-6
 
37. Hlatky MA, Chung S-C, Escobedo J, et al. The effect of obesity on quality of life in patients with diabetes and coronary artery disease. Am Heart J 2010; 159:292-300.
http://dx.doi.org/10.1016/j.ahj.2009.11.004
 
38. Dennett SL, Boye KS, Yurgin NR. The impact of body weight on patient utilities with or without type 2 diabetes: A review of the medical literature. Value Health 2008; 11:478-86.
http://dx.doi.org/10.1111/j.1524-4733.2007.00260.x
 
39. Azman AB, Sararaks S, Rugayah B, et al. Quality of life of the Malaysian General Population: Results from a postal survey using the SF-36. Med J Malaysia 2003; 58:694-711.
 
40. Johnstone MT, Kinzfogl GP. Contemporary Cardiology: Diabetes and Cardiovascular Disease. 2nd ed. New Jersy: Humana Press Inc, 2005.
 
41. Shaw JE, Punjabi NM, Wilding JP, Alber ti KG, Zimmet PZ. Sleep- disordered breathing and type 2 diabetes: A report from the International Diabetes Federation Taskforce on Epidemiology and Prevention. Diabetes Res Clin Pract 2008; 81:2-12.
http://dx.doi.org/10.1016/j.diabres.2008.04.025
 
42. Durmaz T, Özdemir Ö, Özdemir BA, et al. Factors affecting quality of life in patients with coronary heart disease. Turk J Med Sci 2009; 39:343-51.
 
43. Liles DR, Kallen MA, Petersen LA, Bush RL. Quality of life and peripheral arterial disease. J Surg Res 2006; 136:294-301.
http://dx.doi.org/10.1016/j.jss.2006.06.008
 
44. Anderson RM, Fitzgerald JT, Wisdom K, Davis WK, Hiss RG. A comparison of global versus disease- specific quality-of-life measures in patients with NIDDM. Diabetes Care 1997; 20:299-305.
http://dx.doi.org/10.2337/diacare.20.3.299

Association between urinary 8-OHdG and pulse wave velocity in hypertensive patients with type 2 diabetes mellitus

Share this Article

Singapore Med J2014; 55(4): 202-208; http://dx.doi.org/10.11622/smedj.2014053
Association between urinary 8-OHdG and pulse wave velocity in hypertensive patients with type 2 diabetes mellitus

Kotani K, Yamada T
Correspondence: Dr Kazuhiko Kotani, kazukotani@jichi.ac.jp

ABSTRACT
INTRODUCTION Oxidative stress, assessed using 8-hydroxy-2’-deoxyguanosine (8-OHdG), can be associated with arterial stiffness in patients with type 2 diabetes mellitus (T2DM) and/or hypertension (HT). We investigated the correlation between urinary 8-OHdG and pulse wave velocity (PWV) in hypertensive and non-hypertensive T2DM patients with fair glycaemic control to determine the clinical significance of HT as a comorbidity in the diabetic state.
METHODS Clinical data, including traditional cardiovascular risk factors, diabetic complications, prescribed agents, urinary 8-OHdG level and brachial-ankle PWV, was collected from T2DM patients with and without HT. 
RESULTS There were 76 patients (45 men, 31 women; mean age 61 years; mean haemoglobin A1c level 6.5%) in the study cohort. T2DM patients with HT had significantly higher mean PWV than patients without HT (1,597 cm/s vs 1,442 cm/s; p < 0.05). Patients with HT showed no significant difference in 8-OHdG levels relative to those without HT (median 7.9 ng/mg creatinine vs 8.8 ng/mg creatinine; p > 0.05). Simple linear correlation and stepwise multiple linear regression analyses revealed that 8-OHdG levels correlated independently, significantly and positively with PWV among T2DM patients with HT (r = 0.33, p < 0.05; β= 0.23, p < 0.05). No significant correlation was observed between 8-OHdG levels and PWV among T2DM patients without HT.
CONCLUSION In the hypertensive state, oxidative stress can be responsible for the development of arterial stiffness, even in patients with fairly well controlled T2DM. Oxidative stress management may be necessary for the prevention of cardiovascular disease in this population.

Keywords: arterial stiffness, atherosclerosis, DNA damage, oxidative stress, pulse wave velocity
Singapore Med J2014; 55(4): 202-208; http://dx.doi.org/10.11622/smedj.2014053

REFERENCES

1. Sheu WH, Rosman A, Mithal A, et al. Addressing the burden of type 2 diabetes and cardiovascular disease through the management of postprandial hyperglycaemia: an Asian-Pacific perspective and expert recommendations. Diabetes Res Clin Pract 2011; 92:312-21.
http://dx.doi.org/10.1016/j.diabres.2011.04.019
 
2. Hu FB. Globalization of diabetes: the role of diet, lifestyle, and genes. Diabetes Care 2011; 34:1249-57.
http://dx.doi.org/10.2337/dc11-0442
 
3. Chung N, Baek S, Chen MF, et al. Expert recommendations on the challenges of hypertension in Asia. Int J Clin Pract 2008; 62:1306-12.
http://dx.doi.org/10.1111/j.1742-1241.2008.01838.x
 
4. Nishikawa T, Sasahara T, Kiritoshi S, et al. Evaluation of urinary 8-hydroxydeoxy-guanosine as a novel biomarker of macrovascular complications in type 2 diabetes. Diabetes Care 2003; 26:1507-12.
http://dx.doi.org/10.2337/diacare.26.5.1507
 
5. Stehouwer CD, Henry RM, Ferreira I. Arterial stiffness in diabetes and the metabolic syndrome: a pathway to cardiovascular disease. Diabetologia 2008; 51:527-39.
http://dx.doi.org/10.1007/s00125-007-0918-3
 
6. Montezano AC, Touyz RM. Oxidative stress, Noxs, and hypertension: experimental evidence and clinical controversies. Ann Med 2012; 44 Suppl 1:S2-16.
http://dx.doi.org/10.3109/07853890.2011.653393
 
7. Piconi L, Quagliaro L, Ceriello A. Oxidative stress in diabetes. Clin Chem Lab Med 2003; 41:1144-9.
http://dx.doi.org/10.1515/CCLM.2003.177
 
8. Wu LL, Chiou CC, Chang PY, Wu JT. Urinary 8-OHdG: a marker of oxidative stress to DNA and a risk factor for cancer, atherosclerosis and diabetics. Clin Chim Acta 2004; 339:1-9.
http://dx.doi.org/10.1016/j.cccn.2003.09.010
 
9. Negishi H, Njelekela M, Ikeda K, et al. Assessment of in vivo oxidative stress in hypertensive rats and hypertensive subjects in Tanzania, Africa. Hypertens Res 2000; 23:285-9.
http://dx.doi.org/10.1291/hypres.23.285
 
10. Xu S, Touyz RM. Reactive oxygen species and vascular remodelling in hypertension: still alive. Can J Cardiol 2006; 22:947-51.
http://dx.doi.org/10.1016/S0828-282X(06)70314-2
 
11. Leinonen J, Lehtimäki T, Toyokuni S, et al. New biomarker evidence of oxidative DNA damage in patients with non-insulin-dependent DM. FEBS Lett 1997; 417:150-2.
http://dx.doi.org/10.1016/S0014-5793(97)01273-8
 
12. Kanauchi M, Nishioka H, Hashimoto T. Oxidative DNA damage and tubulointerstitial injury in diabetic nephropathy. Nephron 2002; 91:327-9.
http://dx.doi.org/10.1159/000058412
 
13. Espinosa O, Jiménez-Almazán J, Chaves FJ, et al. Urinary 8-oxo-7,8-dihydro-2'-deoxyguanosine (8-oxo-dG), a reliable oxidative stress marker in hypertension. Free Radic Res 2007; 41:546-54.
http://dx.doi.org/10.1080/10715760601164050
 
14. Roselló-Lletí E, de Burgos FG, Morillas P, et al. Impact of cardiovascular risk factors and inflammatory status on urinary 8-OHdG in essential hypertension. Am J Hypertens 2012; 25:236-42.
http://dx.doi.org/10.1038/ajh.2011.202
 
15. Nagayama D, Saiki A, Endo K, et al. Improvement of cardio-ankle vascular index by glimepiride in type 2 diabetic patients. Int J Clin Pract 2010; 64:1796 - 801.
http://dx.doi.org/10.1111/j.1742-1241.2010.02399.x
 
16. Miyashita Y, Saiki A, Endo K, et al. Effects of olmesartan, an angiotensin II receptor blocker, and amlodipine, a calcium channel blocker, on CardioAnkle Vascular Index (CAVI) in type 2 diabetic patients with hypertension. J Atheroscler Thromb 2009; 16:621-6.
http://dx.doi.org/10.5551/jat.497
 
17. Li CH, Wu JS, Yang YC, et al. Increased arterial stiffness in subjects with impaired glucose tolerance and newly diagnosed diabetes but not isolated impaired fasting glucose. J Clin Endocrinol Metab 2012; 97:E658-62.
http://dx.doi.org/10.1210/jc.2011-2595
 
18. Barengo NC, Tuomilehto JO. Blood pressure treatment target in patients with diabetes mellitus–current evidence. Ann Med 2012; 44 Suppl 1:S36-42.
http://dx.doi.org/10.3109/07853890.2012.679961
 
19. Masugata H, Senda S, Murao K, et al. Association between urinary 8-hydroxydeoxyguanosine, an indicator of oxidative stress, and the cardioankle vascular index in hypertensive patients. J Atheroscler Thromb 2012; 19:747-55.
 
20. Yamashina A, Tomiyama H, Takeda K, et al. Validity, reproducibility, and clinical significance of noninvasive brachial-ankle pulse wave velocity measurement. Hypertens Res 2002; 25:359-64.
http://dx.doi.org/10.1291/hypres.25.359
 
21. Oomichi T, Emoto M, Tabata T, et al. Impact of glycemic control on survival of diabetic patients on chronic regular hemodialysis: a 7-year observational study. Diabetes Care 2006; 29:1496-500.
http://dx.doi.org/10.2337/dc05-1887
 
22. Chobanian AV, Bakris GL, Black HR, et al. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension 2003; 42:1206-52.
http://dx.doi.org/10.1161/01.HYP.0000107251.49515.c2
 
23. Imai E, Horio M, Nitta K, et al. Estimation of glomerular filtration rate by the MDRD study equation modified for Japanese patients with chronic kidney disease. Clin Exp Nephrol 2007; 11:41-50.
http://dx.doi.org/10.1007/s10157-006-0453-4
 
24. Toyokuni S, Tanaka T, Hattori Y, et al. Quantitative immunohistochemical determination of 8-hydroxy-2'-deoxyguanosine by a monoclonal antibody N45.1: its application to ferric nitrilotriacetate-induced renal carcinogenesis model. Lab Invest 1997; 76:365-74.
 
25. Yoshida R, Ogawa Y, Kasai H. Urinary 8-oxo-7,8-dihydro-2'-deoxyguanosine values measured by an ELISA correlated well with measurements by high-performance liquid chromatography with electrochemical detection. Cancer Epidemiol Biomarkers Prev 2002; 11:1076-81.
 
26. Rossi MC, Nicolucci A, Pellegrini F, et al. Identifying patients with type 2 diabetes at high risk of microalbuminuria: results of the DEMAND (Developing Education on Microalbuminuria for Awareness of reNal and cardiovascular risk in Diabetes) Study. Nephrol Dial Transplant 2008; 23:1278 - 84.
http://dx.doi.org/10.1093/ndt/gfm798
 
27. Wilkinson CP, Ferris FL 3rd, Klein RE, et al. Proposed international clinical diabetic retinopathy and diabetic macular edema disease severity scales. Ophthalmology 2003; 110:1677-82.
http://dx.doi.org/10.1016/S0161-6420(03)00475-5
 
28. Thompson HJ, Heimendinger J, Haegele A, et al. Effect of increased vegetable and fruit consumption on markers of oxidative cellular damage. Carcinogenesis 1999; 20:2261-6.
http://dx.doi.org/10.1093/carcin/20.12.2261
 
29. Miquel J. Can antioxidant diet supplementation protect against age-related mitochondrial damage? Ann N Y Acad Sci 2002; 959:508-16.
http://dx.doi.org/10.1111/j.1749-6632.2002.tb02120.x
 
30. Nojima H, Watanabe H, Yamane K, et al. Effect of aerobic exercise training on oxidative stress in patients with type 2 diabetes mellitus. Metabolism 2008; 57:170-6.
http://dx.doi.org/10.1016/j.metabol.2007.08.021
 
31. Ozkanlar S, Akcay F. Antioxidant vitamins in atherosclerosis - animal experiments and clinical studies. Adv Clin Exp Med 2012; 21:115-23.
 
32. Kals J, Kampus P, Kals M, et al. Impact of oxidative stress on arterial elasticity in patients with atherosclerosis. Am J Hypertens 2006; 19:902-8.
http://dx.doi.org/10.1016/j.amjhyper.2006.02.003
 
33. Kals J, Kampus P, Kals M, et al. Inflammation and oxidative stress are associated differently with endothelial function and arterial stiffness in healthy subjects and in patients with atherosclerosis. Scand J Clin Lab Invest 2008; 68:594-601.
http://dx.doi.org/10.1080/00365510801930626
 
34. Ha CY, Kim JY, Paik JK, et al. The association of specific metabolites of lipid metabolism with markers of oxidative stress, inflammation and arterial stiffness in men with newly diagnosed type 2 Diabetes. Clin Endocrinol (Oxf) 2012; 76:674-82.
http://dx.doi.org/10.1111/j.1365-2265.2011.04244.x
 
35. Dalfino G, Simone S, Porreca S, et al. Bone morphogenetic protein-2 may represent the molecular link between oxidative stress and vascular stiffness in chronic kidney disease. Atherosclerosis 2010; 211:418-23.
http://dx.doi.org/10.1016/j.atherosclerosis.2010.04.023
 
36. Kato M, Iida M, Goto Y, Kondo T, Yajima I. Sunlight exposure-mediated DNA damage in young adults. Cancer Epidemiol Biomarkers Prev 2011; 20:1622-8.
http://dx.doi.org/10.1158/1055-9965.EPI-11-0228
 
37. Abdilla N, Tormo MC, Fabia MJ, et al. Impact of the components of metabolic syndrome on oxidative stress and enzymatic antioxidant activity in essential hypertension. J Hum Hypertens 2007; 21:68-75.
http://dx.doi.org/10.1038/sj.jhh.1002105
 
38. Martinet W, Knaapen MW, De Meyer GR, Herman AG, Kockx MM. Elevated levels of oxidative DNA damage and DNA repair enzymes in human atherosclerotic plaques. Circulation 2002; 106:927-32.
http://dx.doi.org/10.1161/01.CIR.0000026393.47805.21
 
39. Mazzone T, Chait A, Plutzky J. Cardiovascular disease risk in type 2 diabetes mellitus: insights from mechanistic studies. Lancet 2008; 371:1800-9.
http://dx.doi.org/10.1016/S0140-6736(08)60768-0
 
40. Ogawa S, Mori T, Nako K, Ito S. Combination therapy with renin-angiotensin system inhibitors and the calcium channel blocker azelnidipine decreases plasma inflammatory markers and urinary oxidative stress markers in patients with diabetic nephropathy. Hypertens Res 2008; 31:1147-55.
http://dx.doi.org/10.1291/hypres.31.1147
 
41. Nordstrand N, Gjevestad E, Dinh KN, et al. The relationship between various measures of obesity and arterial stiffness in morbidly obese patients. BMC Cardiovasc Disord 2011; 11:7.
http://dx.doi.org/10.1186/1471-2261-11-7
 
42. Lim S, Choi HJ, Shin H, et al. Subclinical atherosclerosis in a communitybased elderly cohort: the Korean Longitudinal Study on Health and Aging. Int J Cardiol 2012; 155:126-33.
http://dx.doi.org/10.1016/j.ijcard.2011.05.054
 
43. Tomita H, Kawamoto R, Tabara Y, Miki T, Kohara K. Blood pressure is the main determinant of the reflection wave in patients with type 2 diabetes. Hypertens Res 2008; 31:493-9.
http://dx.doi.org/10.1291/hypres.31.493
 
44. Xu L, Jiang CQ, Lam TH, et al. Brachial-ankle pulse wave velocity and cardiovascular risk factors in the non-diabetic and newly diagnosed diabetic Chinese: Guangzhou Biobank Cohort Study-CVD. Diabetes Metab Res Rev 2010; 26:133-9.
http://dx.doi.org/10.1002/dmrr.1059
 
45. Kim WJ, Park CY, Park SE, et al. The association between regional arterial stiffness and diabetic retinopathy in type 2 diabetes. Atherosclerosis 2012; 225:237- 41.
http://dx.doi.org/10.1016/j.atherosclerosis.2012.08.034
 
46. Nakagawa N, Takahashi F, Chinda J, et al. A newly estimated glomerular filtration rate is independently associated with arterial stiffness in Japanese patients. Hypertens Res 2008; 31:193-201.
http://dx.doi.org/10.1291/hypres.31.193
 
47. Maple-Brown LJ, Piers LS, O'Rourke MF, Celermajer DS, O'Dea K. Central obesity is associated with reduced peripheral wave reflection in Indigenous Australians irrespective of diabetes status. J Hypertens 2005; 23:1403-7.
http://dx.doi.org/10.1097/01.hjh.0000173524.80802.5a
 
48. Budimir D, Jeroncic A, Gunjaca G, et al. Sex-specific association of anthropometric measures of body composition with arterial stiffness in a healthy population. Med Sci Monit 2012; 18:CR65-71.
http://dx.doi.org/10.12659/MSM.882457
 
49. Huh JY, Son DJ, Lee Y, et al. 8-Hydroxy-2-deoxyguanosine prevents plaque formation and inhibits vascular smooth muscle cell activation through Rac1 inactivation. Free Radic Biol Med 2012; 53:109-21.
http://dx.doi.org/10.1016/j.freeradbiomed.2012.03.023
 
50. Aso K, Miyata M, Kubo T, et al. Brachial-ankle pulse wave velocity is useful for evaluation of complications in type 2 diabetic patients. Hypertens Res 2003; 26:807-13.
http://dx.doi.org/10.1291/hypres.26.807